Compass Pathways a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience.
Health Technology Insights: Dandy Unveils Next Era of Digital Dentistry With Dandy Vision Intraoral Scanner
As part of this Board transition, Thomas Lönngren will retire from his position on the Board at the end of December after more than six years of service. Mr. Lönngren has been an invaluable counselor across the company’s achievements, including the advancement of the COMP360 program and transition from an early-stage to late-stage clinical company.
Health Technology Insights: FDA Approves Updated WINREVAIR Indication for PAH
“With Compass leading the field of psychedelics and looking ahead to potential commercialization for COMP360, we are grateful to have Dr. Jonas’ extensive experience in neuroscience, an area in which he has consistently driven breakthroughs in treatment,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Along his career, Dr. Jonas has demonstrated a deep commitment to translating cutting-edge science into meaningful clinical impact, which will be highly beneficial as we work to bring COMP360, if approved, to patients in need of new treatment options. On behalf of the entire company and Board, I also want to thank Thomas Lönngren for his insights and thought leadership through the years as he prepares to retire later this year.”
Health Technology Insights: Omada Health Welcomes Thomas Tsang, as Chief Medical Officer
Dr. Jonas is a partner at Cure Ventures, a life sciences venture capital firm focused on advancing transformative therapeutics. Dr. Jonas has held executive leadership roles across various life science organizations. At Sage Therapeutics, Dr. Jonas served as Chief Executive Officer from 2013-2020, and subsequently as Chief Innovation Officer from 2020-2022 and was a member of the Board from 2013-2024. Earlier in his career, he was President of the Regenerative Medicine Division at Shire Pharmaceuticals, guiding strategic direction and driving key R&D milestones. He also held senior roles at ISIS Pharmaceuticals, Forest Laboratories, and Upjohn Laboratories.
Dr. Jonas currently serves on the Board of Directors of Generation Bio Co., and chairs the Board of Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders. Previously, Dr. Jonas served on the board of directors of Karuna Therapeutics, Inc. He has an extensive record of over 40 years of peer-reviewed scientific publications focused on psychiatric disorders, pharmacotherapy and neuropsychopharmacology. Dr. Jonas earned his B.A. from Amherst College and his M.D. from Harvard Medical School. He completed his psychiatry residency at Harvard, where he also served as Chief Resident of Psychopharmacology at McLean Hospital.
“The growing mental health crisis demands bold, science-driven innovation. I am excited to support the Compass team in its mission to transform mental health care through the development of a paradigm-changing treatment. Their pioneering approach has the potential to redefine how we treat some of the most challenging conditions, offering hope to millions of people,” said Dr. Jeffrey Jonas.
Health Technology Insights: INVO, Heidi Health Partner for AI Fertility Tools
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
